Safety assessment of stem cell secretome injection in combination with laser in scar treatment

Investigating the safety of Wharton jelly mesenchymal stem cell secretion injection in combination with erbium laser in hypertrophic scar lesions

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200127046282N58

Enrollment

Registered

2025-11-20

Start date

2025-11-21

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertrophic scar. Keloid scar

Interventions

Intervention 1: Intervention group: Patients will receive three sessions of Erbium Laser plus two cc of stem cells secretome , one month apart. Intervention 2: Control group: Erbium laser patients wil

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: The patient has hypertrophic scars. The patient did not receive any treatment concurrently with the study. The patient has not taken isotretinoin in the past 6 months

Exclusion criteria

Exclusion criteria: Patients with photosensitivity Pregnancy Patient's unwillingness to continue cooperation

Design outcomes

Primary

Measure	Time frame
Scar size. Timepoint: before and 6 month after the intervention. Method of measurement: visioface.	—

Secondary

Measure	Time frame
Side effects. Timepoint: One week after treatment. Method of measurement: Questionnaire and visit.;Patient Satisfaction. Timepoint: six months after treatment. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSona Zare

Skin and Stem cell Research Center of Tehran University of Medical Sciences

sonazarebio@gmail.com+98 21 2665 7438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026